CLEVELAND, Ohio, Nov. 4, 2010 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it has secured three Therapeutic Discovery Project grants as part of the Patient Protection and Affordable Care Act of 2010. These grants were awarded related to Athersys' development of MultiStem ® for the treatment of acute myocardial infarction (AMI), also known as heart attack, and other forms of cardiovascular disease, as well as for the treatment of multiple diseases causing acute tissue damage and chronic inflammation. MultiStem is currently being developed for the treatment of AMI, Graft vs. Host Disease (GvHD) following bone marrow transplant, inflammatory bowel disease, and stroke. Additionally, one of the three awarded grants was secured to advance Athersys' pharmaceutical development program in obesity. Athersys is developing compounds that selectively stimulate the 5HT2c serotonin receptor in the brain, which is known to play an important role in regulating appetite. The Therapeutic Discovery Project grants totaled more than $730,000 in aggregate.
Athersys Secures Multiple Grants To Advance Key Therapeutic Programs In Regenerative Medicine And Obesity
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.